flurandrenolide (cordran) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Flurandrenolide is a potent corticosteroid intended for topical use. Flurandrenolide occurs as white to off-white, fluffy, crystalline powder and is odorless. Flurandrenolide is practically insoluble in water and in the ether. Cordran is primarily effective because of its anti-inflammatory, antipruritic, and vasoconstrictive actions. The mechanism of the anti-inflammatory effect of topical corticosteroids is not completely understood. Corticosteroids with anti-inflammatory activity may stabilize cellular and lysosomal membranes. There is also the suggestion that the effect on the membranes of lysosomes prevents the release of proteolytic enzymes and, thus, plays a part in reducing inflammation. Flurandrenolide is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.   NCATS

Chemistry

  • SMILES: CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)CC[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO
  • InChIKey: POPFMWWJOGLOIF-XWCQMRHXSA-N
  • Mol. Mass: 436.5136
  • ALogP: 2.5
  • ChEMBL Molecule:
    flurandrenolide  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Topical
  • Pro Drug: No

Drug Pricing (per unit)

United States

$0.8578 - $703.6300
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Combination drugs

( flurandrenolide (cordran), neomycin )

Alternative names

33379 | cordran | cordran sp | fluadrenolone | fludrossicortide | fludroxicortida | fludroxicortide | fludroxycortid | fludroxycortide | fludroxycortidum | fluorandrenolone | fluorandrenolone acetonide | fluoroandrenolone acetonide | flurandrenolide | flurandrenolone | flurandrenolone acetonide | haelan | haelan-c | haelan-x

Organizations (11)

Research & Development (3)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (8)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (7)

Approved Indications (1)


 

Skin Diseases (approved 1965)

Experimental Indications - Clinical Trial Phases 1-4 (6)


 

Anorexia (Phase 2)

Cachexia (Phase 2)

Kidney Failure, Chronic (Phase 3)

Peritoneal Dialysis (Phase 3)

Peritoneal Dialysis, Continuous Ambulatory (Phase 3)

Weight Loss (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial Organizations: 3

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue